Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Dermatology: Acne (June 2017)

Posted by Matt Breese on Jun 2, 2017

Find me on:

According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters reveals the bump in restricted commercial and health exchange lives across payer pharmacy benefits. The percentage of covered lives with a PA or step edit policy also increased slightly.


Source: MMIT data as of Q4 2016

Trends:  Recent news highlights some key trends in the dermatology-acne landscape. Over the past 18 months, pharmacy benefit managers have demonstrated their ability to shift restrictions based on the marriage of script claims and market access data. The complexity in this disease area due to generic competition remains significant.

To read the full Reality Check on Dermatology with key findings on clinical characteristics, acne drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Payer, Branding & Marketing